2月15日,FDA要求拜耳公司在尼莫地平(商品名尼莫同)的说明书上增加关于用药方法不当的警告内容。尼莫地平被批准口服改善蛛网膜下腔出血的神经症状。但如果尼莫地平通过静脉注射或其他注射途径给药,会引起严重不良反应甚至死亡。尼莫地平是一种钙通道阻断剂,能降血压;当被静脉注射而不是口服使用时．由于降压作用过于强烈,会导致虚脱而死亡。因此,尼莫地平不得静脉注射或通过其他注射途径给药。 February 15, the FDA asked Bayer Nimodipine (trade name Nemo) the instructions on the use of inappropriate methods of warning content. Nimodipine is approved for oral improvement of neurological symptoms of subarachnoid hemorrhage. However, if nimodipine is given intravenously or by other routes of injection, it can cause serious adverse effects and even death. Nimodipine is a calcium channel blocker that lowers blood pressure; when administered intravenously instead of orally. Due to the hypotensive effect is too strong, can lead to collapse and death. Therefore, nimodipine may not be administered intravenously or by other routes of injection.